Reference Age/Sex GBS subtype CD4 (cells/mm3) IVIG given PLEX given ART given Outcome
Cornblath et al. [11] 22M CIDP Not specified No Yes No Multiple relapses despite PLEX and prednisone; took prednisone with recurrences; died of homicide months after presentation
  31M CIDP Not specified No No No Relapsing course; received prednisone and had resolution of symptoms
  24M CIDP Not specified No No No Relapsing course; recovered without treatment
  45M CIDP Not specified No Yes No PLEX resulted in improvement of neurological symptoms to nearly normal
  37M CIDP Not specified No No No Recovered without treatment
  29F CIDP Not specified No No No Clinical remission with prednisone
  18M AIDP Not specified No Yes No Improvement of symptoms
  27M AIDP Not specified No Yes No Improvement of symptoms
  26M AIDP Not specified No Yes No Improvement of symptoms
Hagberg et al. [23] 56M AIDP Not specified No No No Improvement of symptoms within 4 weeks; able to walk without support at 8 weeks
  69M AIDP Not specified No No No On the ventilator for 12 weeks; resolution of weakness in upper extremities and improvement in lower extremities 5 months later
Vendrell et al. [24] 42M AIDP Not specified No Yes No Improvement of motor weakness by 4 months; moderate quadriparesis 6 months after symptom onset
Conlon [25] 28F AIDP Not specified No No No Died 5 weeks after symptom onset due to ventilator-associated pneumonia
  19F AIDP Not specified No No No Gradual improvement over several weeks, then lost to follow-up
  29F AIDP Not specified No No No Able to walk with support 1 month after symptom onset
Franciotta et al. [26] 25M AIDP 1276 No Yes No Partially improved neurological symptoms with moderate tetraparesis 5 months after symptom onset
Qureshi et al. [13] 30M AIDP 5 No Yes No Unable to walk without assistance 1 year after symptom onset
  33M AIDP 4 Yes No No Strength improved; required a cane to ambulate 1 year after symptom onset
Hassan and Mathew [27] 27M AIDP Not specified Yes No No Complete recovery by week 4 after symptom onset
Bani-Sadr et al. [28] 35M AIDP 149 No No AZT/3TC/RTV/IDV Complete recovery within 2 months from ART initiation
Brannagan and Zhou [20] Not specified AIDP 680 No No No Good recovery with mild dysesthesias
  Not specified AIDP 300 No Yes No Good recovery; recurrent episodes developed 4 years later, responding to IVIG
  Not specified AIDP 430 No Yes No Full recovery
  Not specified AIDP 118 No Yes No Good recovery with dysesthesias
  Not specified AIDP 800 Yes No No Good recovery – able to ambulate; recurrence 10 weeks later – requires steroids and IVIG
  Not specified AIDP 685 Yes No No Good recovery; recurrence and paralysis after 9 weeks – requires steroids and IVIG
  Not Specified AIDP 175 Yes No AZT Died 18 days after symptom onset due to cardiac arrest
  Not specified AIDP 190 No Yes Yes (regimen not specified) Good recovery with mild residual weakness
  Not specified AIDP 55 Yes No Yes (regimen not specified) Good recovery with mild residual weakness
  Not specified AIDP 240 No Yes Yes (regimen not specified) Weakness and reflexes recovered; dysesthesias present
Kumar et al. [29] 21M AIDP Not specified No Yes No Functionally independent at 3-month follow-up; complete resolution at 4-year follow-up
Aggarwal et al. [30] 30M AIDP 400 No No No Patient left the hospital against medical advice
Gisslén et al. [19] 35M AIDP 914 Yes No D4T/3TC/SQV/NLF Improvement 3 months after symptom onset; ART stopped; AIDP recurred 2 months later; IVIG and ART started; symptoms resolved in 7 months; ART discontinued and no recurrence
de Castro et al. [31] 38M AIDP 502 Yes Yes AZT/3TC/IDV, then AZT/3TC/RTV, then AZT/3TC/EFV Two recurrences due to interruption of ART, followed by complete recovery, which was sustained over 3 years when adherent to ART
Wagner and Bromberg [15] 46M AMAN 150 No No Yes (regimen not specified) Complete recovery 12 months after symptom onset
Hiraga et al. [32] 56M FS/GBS 24 Yes No Yes (regimen not specified) Complete recovery with continued ART
Sloan et al. [33] 30M AIDP 408 Yes No AZT/3TC/EFV Complete recovery after 6 months, even after cessation of ART after 6 months
Kumar et al. [34] 38M AIDP 280 Yes No AZT/3TC/EFV Death due to severe respiratory distress during initial hospital stay
Pontali et al. [35] 56M AIDP 710 Yes No No Death on day 8 of hospital stay due to cardiac arrest
Schreiber et al. [9] 45F AIDP 334 Yes No No Complete recovery 5 months after symptom onset
Nishijima et al. [36] 33M AMAN 334 Yes No LPV/RTV/TDF/FTC Able to walk with a cane after 15 months of rehabilitation
*Kume et al. [37] 47M CIDP 466 No No Yes (regimen not specified) Near complete recovery, with mild dysesthesias and normal NCS 6 months after symptom onset; improvement sustained after 2 years of follow-up
Current case 20M AIDP 213 Yes Yes TDF/FTC/RAL Recurrent episodes of AIDP, with progression to CIDP; near complete recovery 12 months after symptom onset
*Article in Japanese; data derived from English abstract.
Abbreviations: 3TC: Lamivudine; AIDP: Acute Inflammatory Demyelinating Polyneuropathy; AMAN: Acute Motor Axonal Neuropathy; ART: Antiretroviral Therapy; AZT: Zidovudine; CIDP: Chronic Inflammatory Demyelinating Polyneuropathy; D4T: Didanosine; EFV: Efavirenz; F: Female; FS: Fisher Syndrome; FTC: Emtricitabine; GBS: Guillain-Barré Syndrome; HIV: Human Immunodeficiency Virus; IDP: Inflammatory Demyelinating Polyneuropathy; IDV: Indinavir; IVIG: Intravenous Immunoglobulin; LPV: Lopinavir; M: Male; NCS: Nerve Conduction Study; NLF: Nelfinavir; PLEX: Plasmapheresis; RAL: Raltegravir; RTV: Ritonavir; SQV: Saquinavir; TDF: Tenofovir.
Table 1: Treatment of IDP in ART-naïve patients with HIV infection.